Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients

Transplantation

Volumn 90, Issue 12, 2010, Pages 1432-1438

  Snydman, David R ^a   Kistler, Kristin D ^b   Ulsh, Paula ^c   Morris, Jonathan ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ProSanos Corporation   (United States)

^c CSL Behring LLC   (United States)

Author keywords

Antiviral; CMV immune globulin; Cytomegalovirus; Outcomes; Pediatric heart transplantation

Indexed keywords

ANTIVIRUS AGENT; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR;

ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CHILD; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME; TREND STUDY;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CONTINENTAL POPULATION GROUPS; CREATININE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; SURVIVAL RATE; SURVIVORS; TIME FACTORS; TISSUE DONORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 78650809968     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ffba7e     Document Type: Article

References (34)

1. Chinnock RE, Baum MF, Larsen R, et al. Rejection management and long-term surveillance of the pediatric heart transplant recipient: The Loma Linda experience. J Heart Lung Transplant 1993; 12: S255.
2. Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 2007; 20: 425.
3. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561.
4. Gambino A, Cerutti A, Feltrin G, et al. Outcome after pediatric heart transplantation: Two decades of a single center experience. Eur J Cardiothorac Surg 2007; 32: 220.
5. Kirk R, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Heart Transplantation Report-2009. J Heart Lung Transplant 2009; 28: 993.
6. Simmonds JD, Fenton MJ, Dawkins HE, et al. CMV causes intimal thickening in the coronary and systemic vasculature of pediatric heart transplant recipients. T J Heart Lung Transplant 2008; 27: S128.
7. Kuhn MA, Jutzy KR, Deming DD, et al. The medium-term findings in coronary arteries by intravascular ultrasound in infants and children after heart transplantation. J Am Coll Cardiol 2000; 36: 250.
8. Potena L, Grigioni F, Ortolani P, et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: A prospective three-dimensional intravascular ultrasound study. Transplantation 2003; 75: 839.
9. Bonaros N, Mayer B, Schachner T, et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis. Clin Transplant 2008; 22: 89.
10. Hodson EM, Craig JC, Strippoli GF, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008: CD003774.
11. Hodson EM, Jones CA, Strippoli GF, et al. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007: CD005129.
12. Snydman DR. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis 2001; 3: 6.
13. Snydman DR. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 1990; 12: S839.
14. Mahle WT, Fourshee MT, Naftel DM, et al. Does Cytomegalovirus serology impact outcome after pediatric heart transplantation? J Heart Lung Transplant 2009; 28: 1299.
15. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928.
16. Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: A comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001; 72: 1647.
17. Bonaros NE, Kocher A, Dunkler D, et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 2004; 77: 890.
18. Potena L, Holweg CTJ, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006; 82: 398.
19. Davies RR, Russo MJ, Mital SR, et al. The influence of CMV status on outcomes following heart transplantation in children-Whose status matters? J Heart Lung Transplant 2009; 28: S251.
20. Hussain T, Burch M, Fenton MJ, et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 2007; 115: 1798.
21. Simmonds J, Fenton M, Dewar C, et al. Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation. Circulation 2008; 117: 2657.
22. Braunlin EA, Hunter DW, Canter CE, et al. Coronary artery disease in pediatric cardiac transplant recipients receiving triple-drug immunosuppression. Circulation 1991; 84: 303.
23. Kanter KR, Naftel DC, Pahl E, et al. Cytomegalovirus (CMV) prophylaxis and infection in pediatric heart transplant recipients. J Heart Lung Transplant 2004; 23: S126.
24. Bonatti H, Tabarelli W, Ruttmann E, et al. Impact of cytomegalovirus match on survival after cardiac and lung transplantation. Am Surg 2004; 70: 710.
25. Kocher AA, Bonaros N, Dunkler D, et al. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant 2003; 22: 250.
26. BoucekMM,Edwards LB, Keck BM, et al. Registry for the international society for heart and lung transplantation: Seventh official pediatric report-2004. J Heart Lung Transplant 2004; 23: 933.
27. Zuppan CW, Wells LM, Kerstetter JC, et al. Cause of death in pediatric and infant heart transplant recipients: Review of a 20-year, singleinstitution cohort. J Heart Lung Transplant 2009; 28: 579.
28. Koskinen P, Lemström K, Bruggeman C, et al. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis. Am J Pathol 1994; 144: 41.
29. Koskinen PK, Kallio EA, Tikkanen JM, et al. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1999; 1: 115.
30. Streblow D, Dumortier J, Moses A, et al. Mechanisms of cytomegalovirusaccelerated vascular disease: Induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol 2008; 325: 397.
31. Borchers AT, Perez R, Kaysen G, et al. Role of cytomegalovirus infection in allograft rejection: A review of possible mechanisms. Transpl Immunol 1999; 7: 75.
32. Fateh-Moghadam S, Bocksch W, Wessely R, et al. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003; 76: 1470.
33. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transpl Infect Dis 2001; 3: 44.
34. Adam E, Melnick J, DeBakey M. Cytomegalovirus infection and atherosclerosis. Cent Eur J Public Health 1997; 5: 99.